Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026
Context Therapeutics Inc. (CNTX)
Company Research
Source: GlobeNewswire
PHILADELPHIA, March 19, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today announced a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 17-22, 2026 in San Diego, CA. The presentation will highlight preclinical data regarding the Company’s asset, CT-202, a Nectin-4 x CD3 TCE. Poster Presentation Details:Title:Targeting solid tumors with pH-dependent dual-specific TCEs: First-in-human development of CT-202Abstract Number: 5392Date and Time:Tuesday, April 21, 2026, 9:00 a.m. – 12:00 p.m. PTSession Category:Clinical ResearchSession:PO.CL05.12 – Redefining Targeted Therapy: Bispecific T-Cell Engagers and Antibody-Drug ConjugatesLocation:Poster Section 48 For more information and to view the Company’s abstract, visit the AACR Annual Meeting website. The pos
Show less
Read more
Impact Snapshot
Event Time:
CNTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CNTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CNTX alerts
High impacting Context Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
CNTX
News
- Context Therapeutics (CNTX) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $9.00 price target on the stock.MarketBeat
- Context Therapeutics (CNTX) had its "buy" rating reaffirmed by Guggenheim. They now have a $5.00 price target on the stock.MarketBeat
- Context Therapeutics (CNTX) had its price target raised by Piper Sandler from $4.00 to $7.00. They now have an "overweight" rating on the stock.MarketBeat
- Context Therapeutics Reports Full Year 2025 Operating and Financial Results [Yahoo! Finance]Yahoo! Finance
- Context Therapeutics GAAP EPS of -$0.38 [Seeking Alpha]Seeking Alpha
CNTX
Sec Filings
- 3/23/26 - Form S-8
- 3/23/26 - Form 8-K
- 3/23/26 - Form 10-K
- CNTX's page on the SEC website